Therapeutic targets and recent advances in protein immunotoxins

Current Opinion in Microbiology

Volumn 15, Issue 3, 2012, Pages 300-309

  Madhumathi J , ^a   Verma, Rama S ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CALICHEAMICIN; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; CHEMOKINE RECEPTOR CXCR3; DIPHTHERIA TOXIN; ENDOGLIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; FIBROBLAST GROWTH FACTOR RECEPTOR; GELONIN; HEAT SHOCK PROTEIN 65; IMMUNOTOXIN; INTERLEUKIN 13; INTERLEUKIN 4; LE(Y) ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESOTHELIN; MOMODIN; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PSEUDOMONAS EXOTOXIN; RANTES; RICIN; SAPORIN; TRANSFERRIN RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE; VASCULOTROPIN;

ACUTE MYELOBLASTIC LEUKEMIA; B CELL LEUKEMIA; BLADDER CANCER; BREAST CANCER; CYTOTOXICITY; ENCEPHALOMYELITIS; ENDOTHELIUM CELL; GENE MUTATION; GLIOBLASTOMA; GRAFT VERSUS HOST REACTION; HASHIMOTO DISEASE; HEAD AND NECK CANCER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; KAPOSI SARCOMA; LUNG NON SMALL CELL CANCER; MOLECULAR WEIGHT; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; OVARY CANCER; PEMPHIGUS VULGARIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL LEUKEMIA; T CELL LYMPHOMA; TUMOR CELL; WEGENER GRANULOMATOSIS;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; IMMUNOTOXINS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

BACTERIA (MICROORGANISMS);

EID: 84864068407     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2012.05.006     Document Type: Review

References (57)

1. Shapira A., Benhar I. Toxin-based therapeutic approaches. Toxins (Basel) 2010, 2:2519-2583.
2. Choudhary S., Mathew M., Verma R.S. Therapeutic potential of anticancer immunotoxins. Drug Discov Today 2011, 16:495-503.
3. Kioi M., Seetharam S., Puri R.K. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin. Mol Cancer Ther 2008, 7:1579-1587.
4. Liu Y., Cheung L.H., Marks J.W., Rosenblum M.G. Recombinant single-chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factor. Int J Cancer 2004, 108:549-557.
5. von Minckwitz G., Harder S., Hövelmann S., Jäger E., Al-Batran S.E., Loibl S., Atmaca A., Cimpoiasu C., Neumann A., Abera A., et al. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res 2005, 7:R617-R626.
6. Zhou X.X., Ji F., Zhao J.L., Cheng L.F., Xu C.F. Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells. J Gastroenterol Hepatol 2010, 25:1266-1275.
7. Polito L., Bortolotti M., Pedrazzi M., Bolognesi A. Immunotoxins and other conjugates containing saporin-s6 for cancer therapy. Toxins (Basel) 2011, 3:697-720.
8. Hu C.C., Ji H.M., Chen S.L., Zhang H.W., Wang B.Q., Zhou L.Y., Zhang Z.P., Sun X.L., Chen Z.Z., Cai Y.Q., et al. Investigation of a plasmid containing a novel immunotoxin VEGF165-PE38 gene for antiangiogenic therapy in a malignant glioma model. Int J Cancer 2010, 127:2222-2229.
9. Di Paolo C., Willuda J., Kubetzko S., Lauffer I., Tschudi D., Waibel R., Plückthun A., Stahel R.A., Zangemeister-Wittke U. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res 2003, 9:2837-2848.
10. Cizeau J., Grenkow D.M., Brown J.G., Entwistle J., MacDonald G.C. Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin. J Immunother 2009, 32:574-584.
11. Zhang Y., Xiang L., Hassan R., Paik C.H., Carrasquillo J.A., Jang B.S., Le N., Ho M., Pastan I. Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res 2006, 12:4695-4701.
12. Posey J.A., Khazaeli M.B., Bookman M.A., Nowrouzi A., Grizzle W.E., Thornton J., Carey D.E., Lorenz J.M., Sing A.P., Siegall C.B., et al. A Phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin Cancer Res 2002, 8:3092-3099.
13. Duff S.E., Li C., Garland J.M., Kumar S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J 2003, 17:984-992.
14. Huang X., Bennett M., Thorpe P.E. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. Prostate 2004, 61:1-11.
15. Forsberg G., Skartved N.J., Wallén-Ohman M., Nyhlén H.C., Behm K., Hedlund G., Nederman T. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity. J Immunother 2010, 33:492-499.
16. Wang Z., Zhang T., Hu H., Zhang H., Yang Z., Cui L., He W. Targeting solid tumors via T cell receptor complementarity-determining region 3delta in an engineered antibody. Cancer Lett 2008, 272:242-252.
17. Kreitman R.J. Immunotoxins for targeted cancer therapy. AAPS J 2006, 8:E532-E551.
18. Lyu M.A., Cao Y.J., Mohamedali K.A., Rosenblum M.G. Cell-targeting fusion constructs containing recombinant gelonin. Methods Enzymol 2012, 502:167-214.
19. LoRusso P.M., Lomen P.L., Redman B.G., Poplin E., Bander J.J., Valdivieso M. Phase I study of monoclonal antibody-ricin A chain immunoconjugate Xomazyme-791 in patients with metastatic colon cancer. Am J Clin Oncol 1995, 18:307-312.
20. Fidias P., Grossbard M., Lynch T.J. A Phase II study of the immunotoxin N901-blocked ricin in small-cell lung cancer. Clin Lung Cancer 2002, 3:219-222.
21. Pastan I., Hassan R., FitzGerald D.J., Kreitman R.J. Immunotoxin treatment of cancer. Annu Rev Med 2007, 58:221-237.
22. Bogner C., Dechow T., Ringshausen I., Wagner M., Oelsner M., Lutzny G., Licht T., Peschel C., Pastan I., Kreitman R.J., Decker T. Immunotoxin BL22 induces apoptosis in Mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression. Br J Haematol 2010, 148:99-109.
23. Robak T. Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment. Cancer Treat Rev 2011, 37:3-10.
24. Dean A., Talpaz M., Kantarjian H., Faderl S., Jabbour E., Ravandi Kashani F., O'Brien S.M., Rosenblum M., Cortes J.E. Phase I clinical trial of the anti-CD33 immunotoxin HuM195/rgel in patients (pts) with advanced myeloid malignancies. J Clin Oncol 2010, 28:15s. (Suppl; Abstr 6549).
25. Zhong R.K., van de Winkel J.G., Thepen T., Schultz L.D., Ball E.D. Cytotoxicity of anti-CD64-ricin a chain immunotoxin against human acute myeloid leukemia cells in vitro and in SCID mice. J Hematother Stem Cell Res 2001, 10:95-105.
26. Tur M.K., Huhn M., Jost E., Thepen T., Brümmendorf T.H., Barth S. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model. Int J Cancer 2011, 129:1277-1282.
27. Du X., Nagata S., Ise T., Stetler-Stevenson M., Pastan I. FCRL1 on chronic lymphocytic leukemia, Hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins. Blood 2008, 111:338-343.
28. Chang C.H., Sapra P., Vanama S.S., Hansen H.J., Horak I.D., Goldenberg D.M. Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin. Blood 2005, 106:4308-4314.
29. Polson A.G., Calemine-Fenaux J., Chan P., Chang W., Christensen E., Clark S., de Sauvage F.J., Eaton D., Elkins K., Elliott J.M., et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res 2009, 69:2358-2364.
30. Baatar D., Olkhanud P., Newton D., Sumitomo K., Biragyn A. CCR4-expressing T cell tumors can be specifically controlled via delivery of toxins to chemokine receptors. J Immunol 2007, 179:1996-2004.
31. Manjarrez-Orduño N., Parkhouse R.M., Santos-Argumedo L. NIM-R7, a novel marker for resting B1 and marginal-zone B lymphocytes, is also expressed on activated T and B cells. Immunology 2003, 109:232-237.
32. Ten Cate B., de Bruyn M., Wei Y., Bremer E., Helfrich W. Targeted elimination of leukemia stem cells; a new therapeutic approach in hemato-oncology. Curr Drug Targets 2010, 11:95-110.
33. LeMaistre C.F. DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications. Clin Lymphoma 2000, 1(Suppl. 1):S37-S40.
34. Nagai T., Tanaka M., Tsuneyoshi Y., Matsushita K., Sunahara N., Matsuda T., Yoshida H., Komiya S., Onda M., Matsuyama T. In vitro and in vivo efficacy of a recombinant immunotoxin against folate receptor beta on the activation and proliferation of rheumatoid arthritis synovial cells. Arthritis Rheum 2006, 54:3126-3134.
35. van Roon J.A., van Vuuren A.J., Wijngaarden S., Jacobs K.M., Bijlsma J.W., Lafeber F.P., Thepen T., van de Winkel J.G. Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcgamma receptor I-directed immunotoxin. Arthritis Rheum 2003, 48:1229-1238.
36. Chen W., Li H., Jia Y., Lv M., Li M., Feng P., Hu H., Zhang L. In vivo administration of plasmid DNA encoding recombinant immunotoxin DT390-IP-10 attenuates experimental autoimmune encephalomyelitis. J Autoimmun 2007, 28:30-40.
37. Jia Y., Li H., Chen W., Li M., Lv M., Feng P., Hu H., Zhang L. Prevention of murine experimental autoimmune encephalomyelitis by in vivo expression of a novel recombinant immunotoxin DT390-RANTES. Gene Ther 2006, 13:1351-1359.
38. Brühl H., Cihak J., Stangassinger M., Schlöndorff D., Mack M. Depletion of CCR5-expressing cells with bispecific antibodies and chemokine toxins: a new strategy in the treatment of chronic inflammatory diseases and HIV. J Immunol 2001, 166:2420-2426.
39. Hossann M., Li Z., Shi Y., Kreilinger U., Büttner J., Vogel P.D., Yuan J., Wise J.G., Trommer W.E. Novel immunotoxin: a fusion protein consisting of gelonin and an acetylcholine receptor fragment as a potential immunotherapeutic agent for the treatment of Myasthenia gravis. Protein Expr Purif 2006, 46:73-84.
40. Trüeb R.M. Autoimmune dermatoses: new therapeutic strategies. Praxis (Bern 1994) 2000, 89:1460-1467.
41. Wang X., Yao C., Jiang Z. Conjugation of methotrexate to immunoglobulins kills macrophages by Fc receptor mediated uptake?. Int J Lab Hematol 2008, 30:185-190.
42. Proby C.M., Ota T., Suzuki H., Koyasu S., Gamou S., Shimizu N., Wahl J.K., Wheelock M.J., Nishikawa T., Amagai M. Development of chimeric molecules for recognition and targeting of antigen-specific B cells in pemphigus vulgaris. Br J Dermatol 2000, 142:321-330.
43. Stepanov A.V., Belogurov A.A., Ponomarenko N.A., Stremovskiy O.A., Kozlov L.V., Bichucher A.M., Dmitriev S.E., Smirnov I.V., Shamborant O.G., Balabashin D.S., et al. Design of targeted B cell killing agents. PLoS One 2011, 6:e20991.
44. Reiners K.S., Hansen H.P., Krüssmann A., Schön G., Csernok E., Gross W.L., Engert A., Von Strandmann E.P. Selective killing of B-cell hybridomas targeting proteinase 3. Wegener's autoantigen. Immunology 2004, 112:228-236.
45. Zocher M., Baeuerle P.A., Dreier T., Iglesias A. Specific depletion of autoreactive B lymphocytes by a recombinant fusion protein in vitro and in vivo. Int Immunol 2003, 15:789-796.
46. Hess P.R., Barnes C., Woolard M.D., Johnson M.D., Cullen J.M., Collins E.J., Frelinger J.A. Selective deletion of antigen-specific CD8+ T cells by MHC class I tetramers coupled to the type I ribosome-inactivating protein saporin. Blood 2007, 109:3300-3307.
47. Vincent B.G., Young E.F., Buntzman A.S., Stevens R., Kepler T.B., Tisch R.M., Frelinger J.A., Hess P.R. Toxin-coupled MHC class I tetramers can specifically ablate autoreactive CD8+ T cells and delay diabetes in nonobese diabetic mice. J Immunol 2010, 184:4196-4204.
48. Li Z., Yu T., Zhao P., Ma J. Immunotoxins and cancer therapy. Cell Mol Immunol 2005, 2:106-112.
49. Pennell C.A., Erickson H.A. Designing immunotoxins for cancer therapy. Immunol Res 2002, 25:177-191.
50. Mathew M., Verma R.S. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. Cancer Sci 2009, 100:1359-1365.
51. Wan L., Zeng L., Chen L., Huang Q., Li S., Lu Y., Li Y., Cheng J., Lu X. Expression, purification, and refolding of a novel immunotoxin containing humanized single-chain fragment variable antibody against CTLA4 and the N-terminal fragment of human perforin. Protein Expr Purif 2006, 48:307-313.
52. Kufer P., Lutterbüse R., Baeuerle P.A. A revival of bispecific antibodies. Trends Biotechnol 2004, 22:238-244.
53. Müller D., Kontermann R.E. Recombinant bispecific antibodies for cellular cancer immunotherapy. Curr Opin Mol Ther 2007, 9:319-326.
54. Asano R., Ikoma K., Kawaguchi H., Ishiyama Y., Nakanishi T., Umetsu M., Hayashi H., Katayose Y., Unno M., Kudo T., Kumagai I. Application of the Fc fusion format to generate tag-free bi-specific diabodies. FEBS J 2010, 277:477-487.
55. Chames P., Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel?. MAbs 2009, 1:539-547.
56. Beck A., Wurch T., Bailly C., Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010, 10:345-352.
57. Holliger P., Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005, 23:1126-1136.